API | galcanezumab-gnlm

galcanezumab-gnlm (emgality) Report issue

Biologics mAb Approved ^FDA

AACT ChEMBL Drugs@FDA

Active Ingredient History

NOW

Galcanezumab, sold under the brand name Emgality, is a humanized monoclonal antibody used for the prevention of migraine. It is also used for cluster headaches. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
galcanezumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Calcitonin gene-related peptide 1 (Homo sapiens) ^UniProt
- Calcitonin gene-related peptide 2 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Drug Pricing (per unit)

United States

$372.1500 - $608.0123

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

galcanezumab | galcanezumab-gnlm | ly2951742 | ly-2951742

Organizations (7)

Research & Development (7)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (1)

Cluster Headache (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (6)

Cluster Headache (Phase 3)

Glossopharyngeal Nerve Diseases (Phase 4)

Healthy Volunteers (Phase 1)

Migraine Disorders (Phase 4)

Osteoarthritis, Knee (Phase 2)

Trigeminal Neuralgia (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 29
# of Trial Organizations: 7

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue